Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of taqman-based real-time PCR

Clinical Chemistry

Volumn 55, Issue 4, 2009, Pages 748-756

  Li, Jin ^a   Wang, Lilin ^a   Jänne, Pasi A ^b   Makrigiorgos, G Mike ^a,c  

^a DNA Repair and Medical Physics ^*

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEOTIDE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P53; TUMOR PROTEIN;

ALLELE; AMPLICON; ARTICLE; CANCER CELL CULTURE; CODON; COLON TUMOR; CONTROLLED STUDY; DENATURATION; DILUTION; ERYTHROLEUKEMIA; EXON; EXPERIMENTAL STUDY; FOWL; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MUTANT; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SAMPLE; SOMATIC MUTATION; TEMPERATURE; VIRUS ONCOGENE; WILD TYPE; DNA DENATURATION; DNA PROBE; GENETICS; METHODOLOGY; MUTATION; POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE;

AVES;

CELL LINE, TUMOR; DNA PROBES; EXONS; GENOTYPE; HUMANS; MALE; MUTATION; NUCLEIC ACID DENATURATION; POLYMERASE CHAIN REACTION; TEMPERATURE; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 64149087406     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.113381     Document Type: Article

References (35)

1. Croce CM. Oncogenes and cancer. N Engl J Med 2008;358:502-11.
2. Bayley H. Sequencing single molecules of DNA. Curr Opin Chem Biol 2006;10:628-37.
3. Marsh S. Pyrosequencing applications. Methods Mol Biol 2007;373:15-24.
4. Jenkins GJ, Chaleshtori MH, Song H, Parry JM. Mutation analysis using the restriction site muta- tion (RSM) assay. Mutat Res 1998;405:209-20.
5. Ragoussis J, Elvidge GP, Kaur K, Colella S. Matrix- assisted laser desorption/ionisation, time-of-flight mass spectrometry in genomics research. PLoS Genet 2006;2:e100.
6. Li J, Berbeco R, Distel RJ, Jänne PA, Wang L, Makrigiorgos GM. s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis. Nucleic Acids Res 2007;35:e84.
7. Yeung AT, Hattangadi D, Blakesley L, Nicolas E. Enzymatic mutation detection technologies. Bio- techniques 2005;38:749-58.
8. Shi C, Eshleman SH, Jones D, Fukushima N, Hua L, Parker AR, et al. LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 2004;1:141-7.
9. Lipsky RH, Mazzanti CM, Rudolph JG, Xu K, Vyas G, Bozak D, et al. DNA melting analysis for detection of single nucleotide polymorphisms. Clin Chem 2001;47:635-44.
10. Liew M, Pryor R, Palais R, Meadows C, Erali M, Lyon E, Wittwer C. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem 2004;50:1156-64.
11. Orum H. PCR clamping. Curr Issues Mol Biol 2000;2:27-30.
12. Li J, Makrigiorgos GM. Anti-primer quenching- based real-time PCR for simplex or multiplex DNA quantification and single-nucleotide polymor- phism genotyping. Nat Protoc 2007;2:50-8.
13. Li J, Wang F, Mamon H, Kulke MH, Harris L, Maher E, et al. Antiprimer quenching-based real-time PCR and its application to the analysis of clinical cancer samples. Clin Chem 2006;52:624-33.
14. Whitcombe D, Theaker J, Guy SP, Brown T, Little S. Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol 1999;17:804-7.
15. Bernard PS, Wittwer CT. Real-time PCR technol- ogy for cancer diagnostics. Clin Chem 2002;48: 1178-85.
16. Makrigiorgos GM. PCR-based detection of minor- ity point mutations. Hum Mutat 2004;23:406-12.
17. De la Vega FM, Lazaruk KD, Rhodes MD, Wenz MH. Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Geno- typing Assays and the SNPlex Genotyping Sys- tem. Mutat Res 2005;573:111-35.
18. Kutyavin IV, Afonina IA, Mills A, Gorn VV, Lukhtanov EA, Belousov ES, et al. 3-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nu- cleic Acids Res 2000;28:655-61.
19. Moore P. Simplifying the probe set. Nature 2005; 435:238.
20. Wilkening S, Hemminki K, Thirumaran RK, Ber- mejo JL, Bonn S, Forsti A, Kumar R. Determina- tion of allele frequency in pooled DNA: compar- ison of three PCR-based methods. Biotechniques 2005;39:853-8.
21. Jänne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006;12:751-8.
22. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008; 14:579-84.
23. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung can- cer. J Clin Invest 2006;116:2695-706.
24. Ogino A, Kitao H, Hirano S, Uchida A, Ishiai M, Kozuki T, et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res 2007;67:7807-14.
25. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-70.
26. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is asso- ciated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
27. Huang C, Taki T, Adachi M, Konishi T, Higash- iyama M, Miyake M. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 1998;16: 2469-77.
28. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8.
29. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
30. de La Motte Rouge T, Valent A, Ambrosetti D, Vielh P, Lacroix L. [Clinical and molecular predic- tors of response to EGFR tyrosine kinase inhibi- tors in non-small cell lung cancer]. Ann Pathol 2007;27:353-63. [French]
31. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.
32. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9.
33. Glaab WE, Skopek TR. A novel assay for allelic discrimination that combines the fluorogenic 5 nuclease polymerase chain reaction (TaqMan) and mismatch amplification mutation assay. Mu- tat Res 1999;430:1-12.
34. Nagai Y, Miyazawa H, Huqun, Tanaka T, Uda- gawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non- small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Can- cer Res 2005;65:7276-82.
35. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mu- tations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.